Medtronic's Reasonable Valuation Aligns With Better Growth Prospects

October 12, 2026 - 00:07

Medtronic plc has followed a path that looks quite different from the rest of the market over the past year. The stock has dropped by more than 7% in the last 12 months, while the broader market has climbed about 17%. This gap in performance brings up a simple question about valuation for investors: has Medtronic become inexpensive enough to make up for its recent struggles?

The company has faced a mix of pressures, including supply chain issues, currency headwinds, and slower recovery in some of its key business segments. These factors have weighed on the share price and kept sentiment cautious. At the same time, there are signs that the worst may be behind it. Revenue trends in several divisions have started to stabilize, and management has pointed to improving conditions in areas like diabetes care and cardiovascular devices.

Analysts note that the current valuation sits below the company's historical average, which could offer a margin of safety if growth accelerates. The dividend yield also remains attractive for income focused investors. Still, the path forward depends on whether Medtronic can deliver on its pipeline and navigate ongoing cost pressures. For now, the stock presents a case where modest expectations meet a potentially brighter outlook.